Vesalio announces it has recently raised $5 million in funding. The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions. “We are very pleased to secure the additional capital funding, which affirms our track record of achievement and the promising clinical results physicians are seeing with NeVa. We are in the process of initiating several prospective clinical studies for regulatory clearance requirements. In addition to the key studies, we will continue to expand our product offering and geographic sales coverage,” remarked Steve Rybka, CEO of Vesalio.
Vesalio Secures Funding